Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Enjoy this offer
* See conditions under "Our services"

Valuation: SpectraCure AB

Market Cap 67.79M 7.1M 6.16M 5.68M 5.32M 9.95M 680M 10.16M 26.25M 328M 26.67M 26.09M 1.14B P/E Ratio 2024
-10.6x
P/E Ratio 2025 -0.79x
Enterprise Value 57.05M 5.98M 5.19M 4.78M 4.48M 8.37M 572M 8.55M 22.09M 276M 22.44M 21.96M 960M EV / Sales 2024
-
EV / Sales 2025 -
Free-Float
85.17%
Yield 2024 *
-
Yield 2025 -
1 day-2.14%
1 week-20.91%
Current month-15.14%
1 month+80.00%
3 months+29.13%
6 months-25.00%
Current year-23.75%
1 week 0.11
Extreme 0.1064
0.15
1 month 0.06
Extreme 0.0583
0.17
Current year 0.06
Extreme 0.0583
0.17
1 year 0.06
Extreme 0.0583
0.38
3 years 0.06
Extreme 0.0583
6.6
5 years 0.06
Extreme 0.0583
13.19
10 years 0.06
Extreme 0.0583
45.15
Manager TitleAgeSince
Chief Executive Officer 54 01/10/2025
Director of Finance/CFO - 01/06/2026
Chief Tech/Sci/R&D Officer - 07/10/2025
Director TitleAgeSince
Director/Board Member 63 31/08/2012
Director/Board Member 72 01/01/2022
Chairman 74 01/01/2022
Date Insider Type Main position Quantity % Market Cap.
26/05/23Buy

Chairman

25,000 0.0257%
30/08/22Buy

Director

25,000 0.0257%
09/07/22Sell

Director

1,048,493 1.0795%
Change 5-day change 1-year change 3-year change Capi.($)
-2.14%-20.91%-66.82%-98.14% 7.31M
-0.42%+4.83%+53.21%+52.23% 1.55B
+1.82%-4.52%-39.59%-43.30% 326M
-1.31%-9.60%-3.42%-50.87% 56.21M
Average -0.51%-7.13%-14.15%-35.02% 485.51M
Weighted average by Cap. -0.08%+2.85%+35.56%+32.67%

Financials

2024 2025
Net sales - -
Net income -23M -2.41M -2.09M -1.93M -1.81M -3.38M -231M -3.45M -8.91M -111M -9.05M -8.86M -387M -56.08M -5.88M -5.1M -4.7M -4.4M -8.23M -563M -8.4M -21.71M -271M -22.06M -21.59M -943M
Net Debt -13.13M -1.38M -1.19M -1.1M -1.03M -1.93M -132M -1.97M -5.08M -63.5M -5.17M -5.05M -221M -10.74M -1.13M -976K -900K -843K -1.58M -108M -1.61M -4.16M -51.93M -4.22M -4.13M -181M
Logo SpectraCure AB
SpectraCure AB (publ) is a Sweden-based company, which is primarily engaged in the healthcare industry. The Company specializes in cancer treatment technology. The Company develops photodynamic therapeutics based on photosensitive materials activated by laser. The Company's method is called interstitial photodynamic therapy (PDT). Interstitial PDT can be used for solid tumors in internal organs, such as cancer in the prostate, pancreas, and the head and neck area, among others. In addition, the Company offers software platform IDOSE for interstitial PDT treatment of solid cancer tumors in internal organs. With SpectraCure’s interstitial PDT method, the patient is given a photoactivated drug - photosensitizer in combination with laser light guided by a dose control system.
Employees
13
Date Price Change Volume
11/06/26 0.1188 kr -2.14% 1,017,910
10/06/26 0.1214 kr -5.75% 1,424,137
09/06/26 0.1288 kr -0.46% 409,484
08/06/26 0.1294 kr -7.57% 2,487,295
05/06/26 0.1400 kr -2.10% 927,510
  1. Stock Market
  2. Stocks
  3. SPEC Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!